Article citationsMore>>

James, N.D., Sydes, M.R., Clarke, N.W., Mason, M.D., Dearnaley, D.P., Spears, M.R., et al. (2016) Addition of Docetaxel, Zoledronic Acid, or Both to First-Line Long-Term Hormone Therapy in Prostate Cancer (STAMPEDE): Survival Results from an Adaptive, Multiarm, Multistage, Platform Randomised Controlled Trial. The Lancet, 387, 1163-1177.
https://doi.org/10.1016/S0140-6736(15)01037-5

has been cited by the following article:

• TITLE: Aminated Cyclopropylmethylphosphonates as Potent Prostate Cancer Inhibitors

  AUTHORS: Abed Al Aziz Al Quntar, Ibrahim Abasy

  KEYWORDS: Prostate Cancer, Cancer, Cyclopropylphophonates, Aminophosphonates, Cyclopropanes, Phosphonates, Alkynylphosphonates, Anti-Cancer, Prostate

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.12 No.7, July 23, 2024

  ABSTRACT: Inspired by the anti-pancreatic promising results of our novel aminated cyclopropylmethylphosphonate compounds, an in vitro anti-prostate cancer activity exploration of these compounds was carried out on human prostate cancer cell line PC-3, and showed potent inhibiting activity at low micromolar concentrations (with an IC50 of approximately 45 μM).